Olopatadine Hydrochloride Nasal Spray
Rx Only
Therapeutic ClassAntihistamine (H1 receptor antagonist)
Common Dose1–2 sprays per nostril twice daily
Max / 24h4 sprays per nostril
PregnancyCategory C
Indications ▼
Seasonal allergic rhinitis: relief of sneezing, nasal itching, rhinorrhea, and congestion caused by pollen exposure.
Perennial allergic rhinitis: symptom control for year-round triggers such as dust mites, pet dander, or mold.
Adjunct therapy for patients not fully controlled with oral antihistamines.
Prevention of nasal allergy symptoms before allergen exposure (prophylactic use).
Mechanism & Pharmacokinetics ▼
Mechanism: Olopatadine selectively blocks H1 receptors in nasal mucosa and stabilizes mast cells, reducing histamine release and inflammatory mediator activity, alleviating nasal allergy symptoms.
Pharmacokinetics: After intranasal administration, systemic absorption is low. Peak plasma concentrations occur in 15–30 minutes. Metabolized in liver and excreted mainly via urine. Half-life ~8–12 hours. Minimal systemic effects due to local application.
Dosage & Administration ▼
| Patient Category | Recommended Dose | Max / 24h |
|---|---|---|
| Adults & Children ≥6 years | 1 spray per nostril twice daily; may increase to 2 sprays per nostril if needed | 4 sprays per nostril |
| Children 2–5 years | 1 spray per nostril once daily | 2 sprays per nostril |
| Children <2 years | Not recommended | – |
Side Effects ▼
Common: bitter taste, nasal irritation, sneezing after application, headache
Occasional: dry nose, mild epistaxis, fatigue
Rare: hypersensitivity reactions including rash or swelling
Contraindications ▼
Hypersensitivity to olopatadine or any component of the nasal spray
Active nasal infection (bacterial, viral, or fungal)
Drug Interaction ▼
No clinically significant drug interactions reported with intranasal use
Concurrent use with other nasal sprays should be separated by at least 5–10 minutes
Pregnancy & Lactation ▼
Use only if clearly needed (Category C)
Low systemic absorption; generally considered compatible with breastfeeding
Clinical / Research Summary ▼
Rapid Symptom Relief: Clinical trials show olopatadine nasal spray significantly reduces sneezing, nasal itching, and rhinorrhea within 30–60 minutes, with sustained relief up to 12 hours.
Comparative Efficacy: Studies demonstrate olopatadine nasal spray is comparable to azelastine and levocetirizine nasal sprays, with improved tolerability and less bitter taste complaints.
Long-Term Use: Well-tolerated for chronic allergic rhinitis management; minimal systemic exposure reduces risk of sedation or cardiovascular effects.
Prophylactic Use: Prevents onset of symptoms if administered prior to allergen exposure, especially in seasonal allergies.
Safety Profile: Low incidence of adverse events in pediatric and adult populations; rare hypersensitivity reactions reported post-marketing.
Patient Counseling Points ▼
Blow nose gently before administration
Shake bottle gently; aim spray toward outer wall of nostril
Do not exceed recommended dose; twice daily dosing is sufficient
Monitor for nosebleeds or irritation; report persistent symptoms to a doctor
Pregnant or breastfeeding women should consult physician before use
Storage & Handling ▼
Store at 2–25°C; protect from light and freezing
Keep out of reach of children
Brand Names (Bangladesh & Global) ▼
Bangladesh (Local Brands):
Global / International Brands:
Olopat
Patanase
Patanase
Olopatadine Nasal Spray
Medical Disclaimer: This clinical summary is for informational purposes only. Always follow guidance from a qualified healthcare professional for dosage, interactions, and use.
.png)
